Peptide drugs have advantages such as good activity, strong specificity, good receptor affinity, weak toxicity and not easy to accumulate in vivo. In recent years, with the rise of new therapies, peptide drugs have developed rapidly and their market scale has been expanding.
According to Frost Sullivan, the global peptide drug market is expected to grow from $62.8 billion in 2020 to $96 billion in 2025, with a compound annual growth rate of 8.8%. It is worth mentioning that peptide is complex and highly technical, so the development and production of difficult, cost is also a challenge. Therefore, the growing market demand for peptide drugs will also promote the growth of peptide CDMO.
Peptide CDMO’s services include CMC services and manufacturing, covering the entire value chain from R&D services, non-GMP intermediates, GMP starting materials, preclinical to commercial scale apis, pharmaceutical formulations and analytical development and validation (excluding clinical trial services). With peptide CDMO, biotechnology and pharmaceutical companies can reduce costs and greatly improve efficiency.
The global peptide CDMO market is projected to grow from $2 billion in 2020 to $4.4 billion in 2025, with a cagR of 17.7%, according to the data. In recent years, more local pharmaceutical companies have emerged in the peptide CDMO market. For example, On June 25, 2021, The company filed for listing on the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Jefferies as co-sponsors. According to Frost Sullivan, the company is one of the world’s four largest providers of peptide CDMO services by 2020 revenue, with a cagR of 26.5% over the record period.
As of June 21, 2021, the company had more than 100 customers in preclinical, phase I, II, and III development of novel peptide drugs. By the end of 2020, the company operates 16 peptide production lines in the United States and China. In 2020, the company has 288 peptide projects in various stages of development in progress, 266 in preclinical and phase I clinical trials, 16 in phase II clinical trials, 2 in phase III clinical trials and 4 in commercial trials.
For another example, on June 3, this year, Shengnobio was listed on the Shanghai Stock Exchange. The company mainly provides pharmaceutical research services for innovative peptides, customized peptide product manufacturing services (CDMO) and peptide drug production technology transfer services for international pharmaceutical enterprises.
It is reported that Shengnuo biotech has successively provided pharmaceutical research services for more than 30 projects for Pag Biotech, Biocteta, and eight plus first-class drug r&d enterprises and scientific research institutions, among which 1 variety has been approved to market and entered the commercialization stage, and 7 peptide innovative drugs have entered the clinical trial stage.
From the perspective of the industry, with the active promotion of innovative drug development and consistency evaluation of generic drugs in China, more peptide innovative drugs and generic drugs will be approved and marketed in the future, and the whole peptide drug market will be further expanded. However, the competition of peptide CDMO will be in the field of innovative drugs, and the companies that can provide CDMO services for peptide innovative drugs may fully benefit from the market dividend of innovative drugs in the future.